More Risk Than Benefit: A Review of Pfizer's Clinical Trials Show the Corporation Knew COVID Injections Did Not Prevent Infection or Transmission and Did Not Even Reduce Overall COVID-19-like Symptoms

From [HERE] The Pfizer COVID-19 vaccine clinical trial did not establish that the vaccine’s clinically consequential benefits outweighed its potential harms. Nor did the trial establish that vaccination reduced the overall burden of COVID-19-like symptoms, let alone that it reduced person-to-person transmission. More than five years later, revisiting the evidence is essential if we are to avoid repeating the same mistakes when the next public-health emergency arrives.

U.S. Health Secretary Robert F. Kennedy Jr.’s recent decision to terminate the COVID-19 emergency use authorization (EUA) declarations invites reconsideration of the evidence that launched this extraordinary regulatory chapter.

The U.S. Food and Drug Administration’s (FDA) first EUA for a COVID-19 vaccine rested on its determination that the known and potential benefits of the Pfizer-BioNTech vaccine outweighed its known and potential risks. Yet the pivotal trial report did not bring those benefits and risks together within a common quantitative framework.

Better late than never: more than five years later, I did — and what I found was startling.

At first glance, the famous 95% efficacy against protocol-defined, laboratory-confirmed symptomatic COVID-19 — based on eight versus 162 cases in a trial that randomized 43,548 participants — seems highly promising.

But when this finding is considered alongside the broader set of participant-relevant outcomes (dispersed across the trial publication, its Supplementary Appendix, and the contemporaneous FDA review materials), the overall clinical picture looks markedly different.

Depending on the counting period used, the vaccine group had 2-8 fewer cases of severe COVID-19, whereas the safety data showed numerical excesses of 4-101 participants across clinically consequential adverse-event categories. These categories are not directly comparable, and some may overlap.

Even so, the evidence did not establish that the vaccine’s clinically consequential benefits outweighed its potential harms. Nor did the trial establish that vaccination reduced the overall burden of COVID-19-like symptoms, let alone that it reduced person-to-person transmission.

Crucially, this conclusion does not rest on hindsight: the relevant evidence was already before the FDA when it issued the EUA.

The full basis for this conclusion is presented in my comprehensive reassessment of the evidence, currently available as a preprint. That reassessment is necessarily detailed because the relevant data are complex, scattered across multiple documents and subject to important methodological and interpretive qualifications.

The present column is not intended to replace that analysis, but to distill several of its central findings and implications for a broader readership.

1. What did the 95% efficacy figure actually measure?

The gap between the headline figure and the overall clinical picture begins with the narrow endpoint and brief follow-up behind the 95% efficacy estimate. That figure applied only to protocol-defined, laboratory-confirmed symptomatic COVID-19 over an average of approximately 44 days.

The trial did not assess asymptomatic infection or person-to-person transmission, and the publicly available record allows SARS-CoV-2 testing to be reconstructed for no more than 8.6% of participants.

It therefore could not establish whether vaccination reduced the overall risk of acquiring or transmitting the virus, or how long its protection against symptomatic disease would last.

This gap later attracted considerable public attention. During a hearing in the European Parliament, a Pfizer executive acknowledged that the vaccine had not been tested for its effect on transmission before entering the market, explaining that the company had needed to “move at the speed of science.”

Yet the facts discussed in that exchange had already been documented before the rollout. The trial’s narrow endpoint and brief follow-up were clear from the published record, and the FDA explicitly acknowledged the absence of direct evidence on asymptomatic infection and transmission when it issued the EUA.

These facts had far-reaching implications. At the time, vaccine mandates and passport systems were presented as tools to reduce transmission in public spaces and protect others — especially older and vulnerable people.

Yet those claims could not be grounded in the trial’s central finding, which concerned only short-term protection against laboratory-confirmed symptomatic COVID-19.

The trial therefore provided no direct basis for using vaccination status as a marker of reduced transmission risk, let alone for treating that status as valid for six months, as some passport systems did.

We should not have been so surprised, then, when it became clear after the EUA that vaccinated people continued to become infected in large numbers and that major waves of transmission persisted even after most adults had been vaccinated. This waning protection against infection was soon documented empirically as well.

For example, a nationwide study from Qatar reported that effectiveness against any documented SARS-CoV-2 infection was negligible during the first two weeks, peaked at 77.5% during the first month after the second dose, and then declined progressively.

Unfortunately, the consequences of this evidentiary gap were concrete: vaccine-passport policies restricted individual rights and placed considerable pressure on people to undergo a novel medical intervention, even though the evidence available at authorization had not established that vaccination reduced transmission or protected others.

2. Did vaccination reduce the overall burden of symptoms?

Not only did the trial fail to establish that vaccination prevented infection or transmission; it did not even establish that vaccinated participants experienced fewer COVID-19-like symptoms overall.

That may sound surprising. Let me explain. [MORE]